Expert analysis on medical aesthetics trends, competitive intelligence, and practice growth strategies.
An AAOS 2026 study showing GLP-1 drugs accelerate bone loss 1.5x faster has hit 1.4M views — and med spas offering regenerative injectables are perfectly positioned to capture the panic.
Read more → 2026-04-10GLP-1 weight loss drugs are creating a wave of skin laxity patients—and the practices bundling tightening protocols are pulling $89k/month while competitors miss the shift.
Read more → 2026-04-07Allergan's TrenibotE Phase 3 data debuted at AAD2026 as GLP-1-driven 'Ozempic face' patients flood aesthetics practices. Here's what the clinical data and competitive benchmarks mean for your practice.
Read more → 2026-04-03Men's treatments surged 40% in five years, but 25% thicker skin demands adjusted dosing. Practices adapting now are pulling ahead in local reviews—here's the data.
Read more → 2026-03-31Andrew Huberman's viral "fusion reset" prediction is reshaping what patients want from med spas. Here's the clinical evidence, market data, and competitive intelligence behind the shift.
Read more → 2026-03-27Cheap GLP-1 generics are accelerating weight loss adoption—and driving a post-weight-loss aesthetics boom. Here's what 9,371 practices' review data reveals.
Read more → 2026-03-24Viral posts on 'Ozempic vagina' and GLP-1 body atrophy are converting weight-loss patients into aesthetics consumers. Here's what the review data shows across 9,371 practices.
Read more → 2026-03-19PCL-based biostimulators are reshaping patient expectations in aesthetics. Here's what the data from 9,371 practices reveals about the shift from volume to regeneration.
Read more → 2026-03-17BMJ alerts flag rising Botox and filler complications as the aesthetics market races toward $180B. Here's what review data from 9,371 practices reveals about who patients trust—and why.
Read more → 2026-03-12GLP-1 demand is reshaping med spa revenue. Only top practices are bundling weight loss with aesthetics—and they're seeing measurable gains. Here's what 9,371 practices reveal.
Read more → 2026-03-10Biostimulators are reshaping injectable strategy in 2026. Practices adding them to multimodal regimens are averaging 20% more reviews. Here's what the data shows.
Read more → 2026-03-05Google searches for peptides are up 144% YoY while X posts on peptide stacks earn 3x the engagement of neurotoxin content. Here's what the clinical evidence and market data actually say.
Read more → 2026-03-02GLP-1 drugs are projected to hit $45B+ in 2026 revenue—and they're sending patients straight to med spas with significant facial volume loss. Here's what clinicians, analysts, and patients need to know.
Read more →